Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259255 · ClinicalTrials.gov registry record
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
A clinical trial, sponsored by Shionogi.
- Completed
- Registry status
- 74
- Enrollment target
NCT04259255: Completed study, sponsored by Shionogi.
NCT04259255 is a clinical trial that has completed, run by Shionogi. The registered enrollment target is 74 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04259255 has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- 74 participants
- Enrollment target
Study Summary
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.
Primary Outcome
Collection of blood and/or urine samples for 8-F2 isoprostanes.
Interventions
- DRUG Edaravone (Radicava®/Radicava ORS®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2024-11-24 |
What the finished NCT04259255 record still lists
NCT04259255 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 74 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Edaravone (Radicava®/Radicava ORS®) is the first listed.
NCT04259255 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04259255 about?
NCT04259255 is a clinical study titled "Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)". REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.
What is the current status of trial NCT04259255?
This trial is currently completed. The enrollment target is 74 participants. The study started on 2019-10-21. Estimated completion is 2024-11-24.
What interventions are being tested in trial NCT04259255?
The interventions under investigation include: Edaravone (Radicava®/Radicava ORS®) (DRUG).
Who is sponsoring clinical trial NCT04259255?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI